Skip to main content
SpringerLink
Log in

Medikamente zur Behandlung von Abhängigkeit und Entzugssymptomen

  • Chapter
Handbuch der Psychopharmakotherapie

  • 2556 Accesses

Auszug

Alkohol ist einedirty drug und interagiert mit zahlreichen Neurotransmittern im Gehirn, inklusive Dopamin, Serotonin, GABA, Glutamat und Opioiden. Die Interaktionen sind komplex, da Alkohol in unterschiedlicher Dosierung die Rezeptoren unterschiedlich stark beeinflusst und eine Akute und eine chronische Alkoholwirkung zu unterscheiden sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anton RF, Swift RM (2003) Current pharmacotherapies for alcoholism: U.S. Perspective. Am J Addict 12(Suppl 1): 553–568

    Google Scholar 

  • Anton RF, Moak DH, Waid L, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156: 1758–1764

    PubMed  CAS  Google Scholar 

  • Anton, RF, Moak DH, Latham PK, Wald LR, Malcolm RJ, Dias JK, Roberts JS (2001) Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 21: 72–77

    Article  PubMed  CAS  Google Scholar 

  • Anton RF, O’Malley SS, Ciraulo DA et al (2006) Combined pharmacotheraples and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003–2017

    Article  PubMed  CAS  Google Scholar 

  • Balldin J, Berglund M, Borg S et al (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27: 1142–1149

    Article  PubMed  CAS  Google Scholar 

  • Baltieri DA, de Andrade AG (2003) Efficacy of a camprosate in the treatment of alcohol-dependent outpatients. Rev Bras Psiquiatr 25: 156–159

    Article  PubMed  Google Scholar 

  • Barrias JA, Chabac S, Ferreira L, Fonte A, Potgieter AS (1997) Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psyquiatr Clin 18: 49–160

    Google Scholar 

  • Berglund M, Andreasson S, Franck J, Fridell M, Hakanson I, Johansson BA (2001) Treatment of alcohol and drug abuse-an evidence-based review. Swedish Council on Technology Assessment in Health Care (SBU); Vol 1: Report No. 156

    Google Scholar 

  • Besson J, Aeby, F, Kasas A, Lehert P, Potgieter A (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcoholism: Clin Exp Res 22(3): 573–579

    Article  CAS  Google Scholar 

  • Bouza C, Magro A, Muñoz A, Amate JM (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99: 811–828

    Article  PubMed  Google Scholar 

  • Cahill K, Stead L, Lancaster T (2007) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 24(1): CD006103

    Google Scholar 

  • Carroll KM, Nich C, Ball SA, McCance E, Frankforter TL, Rounsaville BJ (2000) One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 95: 1335–1349

    Article  PubMed  CAS  Google Scholar 

  • Chick J, Gough K, Falkowski W et al (1992) Disulfiram treatment of alcoholism. Br J Psychiatry 161: 84–89

    PubMed  CAS  Google Scholar 

  • Chick J, Howlett H, Morgan MY, Ritson B (2000a) United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcoholism 35: 176–187

    Article  CAS  Google Scholar 

  • Chick J, Anton R, Checinski K et al (2000b) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35: 587–593

    PubMed  CAS  Google Scholar 

  • Chu NS (1979) Carbamazepine: prevention of alcohol withdrawal selzures. Neurology 29: 1397–1401

    PubMed  CAS  Google Scholar 

  • Croop RS, Faulkner EB, Labriola DF (1997) The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psychiatry 54: 1130–1135

    PubMed  CAS  Google Scholar 

  • de Lima MS, de Oliveira Soares BG, Reisser AA, Farrell M (2002) Pharmacological treatment of cocaine dependence: a systematic review. Addiction 97: 931–949

    Article  PubMed  Google Scholar 

  • Dole VP, Nyswander M (1965) A medical treatment for diacetylmorphine (heroin) addiction — a clinical trial with methadone hydrochloride. JAMA 193: 80–84

    Google Scholar 

  • Froehlich JC, Zweifel M, Harts J, Lumeng L, Li TK (1991) Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology (Berl) 103: 467–472

    Article  CAS  Google Scholar 

  • Fuller RK, Branchey L, Brightwell DR et al (1986) Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 256: 1449–1455

    Article  PubMed  CAS  Google Scholar 

  • Gastpar M, Bonnet U, Boning J et al (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 22(6): 592–598

    Article  PubMed  CAS  Google Scholar 

  • Geerlings PJ, Ansoms C, van den Brink W (1997) Acamprosate and prevention of relapse in alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in The Netherlands, Belgium and Luxembourg. Eur Addict Res 3: 129–137

    Article  Google Scholar 

  • Gianoulakis C, de Waele JP (1994) Genetics of alcoholism: role of the endogenous opioid system. Metab Brain Dis 9: 105–131

    Article  PubMed  CAS  Google Scholar 

  • Gonzales D, Rennard SI, Nides M et al and Varenicline Phase 3 Study Group (2006). Varenicline, a 42 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 296: 47–55

    Article  PubMed  CAS  Google Scholar 

  • Gual A, Lehert P (2001) Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcoholism 36(5): 413–418

    Article  CAS  Google Scholar 

  • Guardia J, Caso C, Arias F et al (2002) A double-blind, placebo controlled study of naltrexone in the treatment of alcohol dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 26: 1381–1387

    PubMed  CAS  Google Scholar 

  • Heinala P, Alho H, Kilanmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD (2001) Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychophamacol 21: 287–292

    Article  CAS  Google Scholar 

  • Heinz A, Batra A (2003) Neurobiologie der Alkohol-und Nikotinabhängigkeit. Kohlhammer, Stuttgart

    Google Scholar 

  • Hersh D, Van Kirk JR, Kranzler HR (1998) Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (Berl) 139(1): 44–52

    Article  CAS  Google Scholar 

  • Holbrook AM, Crowther R, Lotter A, Cheng C, King D (1999) Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ 9: 649–655

    Google Scholar 

  • Hopkins JS, Garbutt JC, Poole CL, West SL, Carey TS (2002) Naltrexone and acamprosate: meta-analysis of two mediacal treatment for alcoholism. Alcohol Clin Exp Res 36(Suppl): 751

    Google Scholar 

  • Johnson BA, Ait-Daoud N (2000) Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 149: 327–344

    Article  PubMed  CAS  Google Scholar 

  • Johnson BA, Roache JD, Javors MA et al (2000) Ondansetron for reduction of drinking among blologically predisposed alcoholic patients. JAMA 284: 963–971

    Article  PubMed  CAS  Google Scholar 

  • Johnson BA, Ait-Daoud N, Bowden CL et al (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361: 1677–1685

    Article  PubMed  CAS  Google Scholar 

  • Jorenby DE, Hays JT, Rigotti NA et al and Varenicline Phase 3 Study Group (2006) Efficacy of varenicline, anα4bβ2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296: 56–63

    Article  PubMed  CAS  Google Scholar 

  • Kiefer F, Jahn H, Tarnaske T et al (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60: 92–99

    PubMed  CAS  Google Scholar 

  • Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C, Anton RF (2004) Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res 28: 1710–1717

    Article  PubMed  CAS  Google Scholar 

  • Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR (2002) Potential neuro-protective effects of acamprosate. Alc Clin Exp Res 26: 586–592

    Article  CAS  Google Scholar 

  • Kosten Tr, O’Connor PG (2003) Management of drug and alcohol with-drawal. N Engl J Med 348: 1786–1795

    Article  PubMed  CAS  Google Scholar 

  • Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25: 1335–1341

    Article  PubMed  CAS  Google Scholar 

  • Kranzler HR, Modesto-Lowe V, Van Kirk J (2000) Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 22: 493–503

    Article  PubMed  CAS  Google Scholar 

  • Krishnan-Sarin S, Wand GS, Li XW, Portoghese PS, Froehlich JC (1998) Effect of muopioid receptor blockade on alcohol intake in rats bred for high alcohol drinking. Pharmacol Blochem Behav 59: 627–635

    Article  CAS  Google Scholar 

  • Krystal JH, Cramer JA, Krol WF et al (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345: 1734–1739

    Article  PubMed  CAS  Google Scholar 

  • Ladewig D, Knecht T, Leher P, Fendl A (1993) Acamprosate — a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch 50: 182–188

    PubMed  CAS  Google Scholar 

  • Latt NC, Jurd S, Houseman J, Wutzke SE (2002) Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 176(11): 530–534

    PubMed  Google Scholar 

  • Lee A, Tan S, Lim D et al (2001) Naltrexone in the treatment of alcoholism — an effectiveness study in Singapore. Drug Alcohol Rev 20: 193–199

    Article  Google Scholar 

  • Lhuintre JP, Moore N, Tran G et al (1990) Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 25: 613–622

    PubMed  CAS  Google Scholar 

  • Lhuintre JP, Daoust M, Moore ND et al (1985) Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1: 1014–1016

    Article  PubMed  CAS  Google Scholar 

  • Lucht M, Kuehn KU, Armbruster J et al (2003) Alcohol withdrawal treatment in intoxicated vs, non-into xicated patients: a controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam. Alcohol Alcohol 38: 168–175

    PubMed  CAS  Google Scholar 

  • Majumdar SK (1990) Chlormethiazole: current status in the treatment of the acute ethanol withdrawal syndrome. Drug Alcohol Depend 27: 201–207

    Article  Google Scholar 

  • Malcolm R, Myrick H, Brady KT, Ballenger JC (2001) Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict 10(Suppl): 16–23

    PubMed  Google Scholar 

  • Mann K, Rommelspacher H (1999) Alkohol. In: Gastpar M, Mann K, Rommelspacher H (Hrsg) Lehrbuch der Suchterkrankungen. Thieme, Stuttgart

    Google Scholar 

  • Mann K, Lehert P, Morgan MY (2004) Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs 18: 485–504

    Article  PubMed  CAS  Google Scholar 

  • Mason BJ (2001) Results of the multicenter study of acamprosate in the treatment of alcoholism. Biol Psychiatry 48: 77

    Google Scholar 

  • Mason BJ, Salvato FR, Willams LD et al (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56: 719–724

    Article  PubMed  CAS  Google Scholar 

  • Mayo-Smith MF (1997) Pharmacological management of alcohol with-drawal: a metaanalysis and evidence-based practice guideline: American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 278: 144–151

    Article  PubMed  CAS  Google Scholar 

  • Miotto K, McCann M, Basch J, Rawson R, Ling W (2002) Naltrexone and dsyphoria: factor or myth? Am J Addict 11: 151–160

    Article  PubMed  Google Scholar 

  • Monti PM, Rohsenow DJ, Swift RM et al (2001) Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 25: 1634–1647

    Article  PubMed  CAS  Google Scholar 

  • Morley KC, Teesson M, Reid SC et al (2006) Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 101: 1451–1462

    Article  PubMed  Google Scholar 

  • Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E (2001) Naltrexone for alcohol dependence. Addiction 96(11): 1565–1573

    Article  PubMed  CAS  Google Scholar 

  • Mucha RF, Herz A (1985) Motivational properties, of kappa-and muoploid receptor agonists studied with place and taste preference conditioning procedure. Psychopharmacology (Berl) 86: 274–280

    Article  CAS  Google Scholar 

  • Mundle G, Banger M, Mugele B, Stetter F, Soyka M, Veltrup C, Schmidt LG (2003) AWMF-Behandlungsleitilnle: Akutbehandlung alkoholbezogener Störungen. Sucht 49: 147–167

    Google Scholar 

  • Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E, Investigators K.A.C.T. (2003) Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 38: 135–141

    PubMed  CAS  Google Scholar 

  • Niederhofer H, Staffen W (2003) Acamprosate and its efficacy in treating alcohol dependent adolescents. Eur Child Adolesc Psychiatry 12: 144–148

    Article  PubMed  Google Scholar 

  • O’Malley SS, Froehlich JC (2003) Advances in the use of naltrexone: an integration of preclinical, and clinical findings. Recent Dev Alcohol 16: 217–243

    Article  Google Scholar 

  • O’Malley SS, Jaffe AJ, Chang G et al (1992) Natrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49: 876–887

    Google Scholar 

  • O’Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R, Meyer RE, Rounsaville B (1996) Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 53: 217–224

    Google Scholar 

  • O’Malley SS, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J, O’Connor PG (2003) Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specially care: a nested sequence of 3 randomized trials. Arch Intern Med 163: 1695–1704

    Article  Google Scholar 

  • Oslin D, Liberto JG O’Brien J, Krois S, Norbeck J (1997) Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 5: 324–332

    PubMed  CAS  Google Scholar 

  • Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P (1995) Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 30: 239–247

    PubMed  CAS  Google Scholar 

  • Pelc I, Le Bon O, Lehert P, Verbanck P (1992) Acamprosate in the treatment of alcohol dependence: a six month postdetoxification study. In: Soyka M (ed) Acamprosate in relapse prevention of alcoholism. Springer, Berlin Heidelberg New York, pp 133–142

    Google Scholar 

  • Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P (1997) Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dosefinding study. Br J Psychiatry 171: 73–77

    Article  PubMed  CAS  Google Scholar 

  • Peters DH, Faulds D (1994) Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 47: 1010–1032

    Article  PubMed  CAS  Google Scholar 

  • Poldrugo F (1997) Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 92: 1537–1546

    Article  PubMed  CAS  Google Scholar 

  • Richmond R, Zwar N (2003) Review of buproprion for smoking cessation. Drug Alcohol Rev 22: 203–220

    Article  PubMed  Google Scholar 

  • Rösner S, Leucht S, Lehert P, Soyka M (2007) Acamprosate supports abstinence, naltraxone prevents excessive drinking. Evidence from a meta-analysis with unreported outcomes. J Psychopharmacol, In press

    Google Scholar 

  • Rousseaux JP, Hers D, Ferauge M (1996) Does acamprosate influence alcohol consumption of weaned alcoholics? J Pharm Belg 51: 65–68

    Google Scholar 

  • Rubio G, Jimenez-Arriero MA, Ponce G, Palomo T (2001) Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 36: 419–425

    PubMed  CAS  Google Scholar 

  • Sass H, Soyka M, Mann K, Zieglgänsberger W (1996) Relapse prevention by acamprosate: results from a placebo controlled study in alcohol dependence. Arch Gen Psychiatry 53: 673–680

    PubMed  CAS  Google Scholar 

  • Slattery J, Chick J, Cochrane M et al (2003) Prevention of relapse in alcohol dependence. Health Technology Assessment Report 3 Health Technology Board of Scotland Glasgow

    Google Scholar 

  • Soyka M (1995) Die Alkoholkrankheit-Diagnostik und Therapie. Chapman & Hall, Weinheim

    Google Scholar 

  • Soyka M (2003) Cannabis und mental health. Schmerz 17: 268–273

    Article  PubMed  CAS  Google Scholar 

  • Soyka M, Chick J (2003) Use of acamprosate and opioid antagonists of alcohol dependence: European perspective. Am J Addict 12(Suppl 2): S69–80

    Article  Google Scholar 

  • Soyka M, Roesner S (2006) New pharmacological approaches for treatment of alcoholism. Expert Opin Pharmacother 7: 2341–2353

    Article  PubMed  CAS  Google Scholar 

  • Soyka M, Morhart-Klute V, Horak M (2002) A combinantion of carbamazepine/tiapride in outpatient alcohol detoxification-results from an open clinical study. Eur Arch Psychiatry Clin Neurosci 252: 197–200

    Article  PubMed  Google Scholar 

  • Soyka M, Schmidt P, Franz M et al (2006a) Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients. Eur Arch Psychiatry Clin Neurosci 256: 395–401

    Article  PubMed  Google Scholar 

  • Soyka M, Schmidt F, Schmidt P (2006b) Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence. Pharmacopsychiatry 39: 30–34

    Article  PubMed  CAS  Google Scholar 

  • Soyka M, Banzer K, Erbas B, Koller G, Backmund M (2006c) Substitutionsbehandlung Drogenabhängiger — rechtliche Grundlagen und neue Ergebnisse der Therapieforschung. Nervenheikunde 25: 286–294

    Google Scholar 

  • Spanagel R, Zieglgänsberger W (1997) Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 18: 37–65

    Article  Google Scholar 

  • Spanagel R, Putzke J, Stefferl A, Schobitz B, Zieglgansberger W (1996) Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol 3: 45–50

    Article  Google Scholar 

  • Spanagel R, Pendyala G, Abarca C et al (2005) The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nature Med 11(2): 23–24

    Google Scholar 

  • Stuppaeck CH, Pycha R, Miller C, Whitworth AB, Oberbauer H, Fleischhacker WW (1992) Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol 27: 153–158

    PubMed  CAS  Google Scholar 

  • Tabakoff B, Hoffman PL (1995) The biological aspects of alcoholism: implications for prevention treatment and policy. Hogrefe & Huber, Seattle, WA

    Google Scholar 

  • Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000) Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35 202–209

    PubMed  CAS  Google Scholar 

  • Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR and Varenicline Phase 3 Study Group (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296: 64–71

    Article  PubMed  CAS  Google Scholar 

  • Tsai G, Gasfriend DR, Coyle JT (1995) The glutamatergic basis of human alcoholism. Am J Psychiatry 152: 332–340

    PubMed  CAS  Google Scholar 

  • Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876–880

    PubMed  CAS  Google Scholar 

  • Volpicelli JR, Watson NT, King AC, Sherman CE, O’Brien CP (1995) Effect of naltrexone on alcohol »high« in, alcoholics. Am J Psychiatry 152: 613–615

    PubMed  CAS  Google Scholar 

  • Volpicelli JR, Rhines JS, Rhines KC, Volpicelli LA, Alterman AI, O’Brien CP (1997) Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 54: 737–742

    PubMed  CAS  Google Scholar 

  • Whitworth AB, Fischer F, Lesch OM et al (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 25: 1438–1442

    Article  Google Scholar 

Download references

Authors
  1. Michael Soyka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Rösner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Max-Planck-Institut für Psychiatrie, Kraepelinstraße 2-10, 80804, München

    Florian Holsboer

  2. Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum der Rheinisch-Westfälischen Technischen Hochschule Aachen, Pauwelsstraße 30, 52074, Aachen

    Gerhard Gründer

  3. Ehemals: Psychiatrische Klinik und Poliklinik der Johannes-Gutenberg-Universität Mainz, Untere Zahlbacher Straße 8, 55131, Mainz

    Otto Benkert

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Soyka, M., Rösner, S. (2008). Medikamente zur Behandlung von Abhängigkeit und Entzugssymptomen. In: Holsboer, F., Gründer, G., Benkert, O. (eds) Handbuch der Psychopharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68748-1_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68748-1_33

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20475-6

  • Online ISBN: 978-3-540-68748-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation